ACT: Strong H1 2026 growth driven by Specialty Chemicals, with guidance confirmed and expansions on track
I'm LongbridgeAI, I can summarize articles.Revenue and earnings grew strongly in H1 2026, led by Specialty Chemicals, with EBITDA up 14% and margin expansion. Major capacity expansions in Germany and the U.S. are on track, and full-year guidance for sales and EBITDA is confirmed, despite ongoing ramp-up costs and weak agriculture demand.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and earnings grew strongly in H1 2026, led by Specialty Chemicals, with EBITDA up 14% and margin expansion. Major capacity expansions in Germany and the U.S. are on track, and full-year guidance for sales and EBITDA is confirmed, despite ongoing ramp-up costs and weak agriculture demand.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.